Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET
Company Participants
Juli Miller - Head-Investor Relations
Adrian Rawcliffe - Chief Executive Officer
Dennis Williams - Senior Vice President, Late Stage Development
Gavin Wood - Chief Financial Officer
John Lunger - Chief Patient Supply Officer
Elliot Norry - Chief Medical Officer
Conference Call Participants
Tony Butler - Roth
Anthony Rodriguez - Cowen & Company
Jonathan Chang - SVP Leerink
Mara Goldstein - Mizuho Securities
Danya Hail - Jones Research
Operator
Good morning, everyone. Welcome to the Adaptimmune’s Q2 Financial and Business Update Conference Call. I would now like to turn the meeting over to Juli Miller. Please go ahead, Ms. Miller.
Juli Miller
Good morning. And welcome to Adaptimmune’s conference call to discuss our second quarter 2022 financial results and business update. I would ask you to review the full text of our forward- looking statement from this morning’s press release. We anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC. Adrian Rawcliffe, our Chief Executive Officer, and Gavin Wood, our Chief Financial Officer, and Dennis Williams, our Senior Vice President of Late-Stage Development and Regulatory Affairs are here with me for the prepared portion of the call. Other members of our management team will be available for Q&A.
With that, I’ll turn the call over to Adrian Rawcliffe. Ad?
Adrian Rawcliffe
Thank you, Juli, and thank you, everyone, for joining us. In 2022 we are focused on four things to drive value for our stakeholders. One, submitting the BLA for afami-cel, our first-generation MAGE-A4 targeted product; two, building out the MAGE-A4 franchise, three, scaling up our manufacturing capabilities; and four, progressing our allogeneic platform. We’re building a Company to deliver a long-term vision of multiple marketed cell therapies for cancer, including allogeneic therapies. In the near and mid-term, we are focused on our MAGE-A4 franchise. We’re on track to submit our first BLA for afami-cel for the treatment of synovial sarcoma in Q4, and Dennis is going to update you on our progress towards submission. If approved, this will be the first commercially available engineered TCR cell therapy for solid tumors.
Adaptimmune has received tremendous support for afami-cel from healthcare providers, clinical centers of excellence, and from patient groups, for which we’re incredibly grateful, as patients are at the heart of every step that we take. We’re honored to announce that in September we will accept the Vision of Hope Award from the Sarcoma Foundation of America.